「a1」の検索結果
434件：396～400件目を表示
-
Overseas Activities | SENJU Pharmaceutical
Eye health and pharmaceutical development have no borders. We engage in international activities with a view to the future of pharmaceuticals, transcending national and corporate boundaries. As we ent
https://www.senju.co.jp/english/global/ -
December 22, 2025 General Announcement Senju Pharmaceutical Co., Ltd. Mochida Pharmaceutical Co., Ltd. Obtained manufacturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a
https://www.senju.co.jp/system/files/content_news/2025-12/ENG_20251222_0.pdf -
December 22, 2025 General Announcement Senju Pharmaceutical Co., Ltd. Mochida Pharmaceutical Co., Ltd. Obtained manufacturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a
https://www.senju.co.jp/system/files/content_news/2025-12/ENG_20251222.pdf -
MytearV | OTC Products, etc. | Products | SENJU Pharmaceutical
Category 2 OTC medicines Mytear® V Resolves redness of the eye and provides healthy and clear eyes. CHARACTERISTICS Compounded with "tetrahydrozoline hydrochloride", a component to relieve r
https://www.senju.co.jp/english/products/mytearv.html -
学会発表実績 | 研究開発活動 | 千寿製薬株式会社
V1 antagonist Satoko Doi1, Satomi Kikuchi2, Yoshihisa Nakano2, Shigeki Matsumoto2, Yoshinori Yamagiwa1, Kotaro Yamada1, Hideya Yonekura1, Gen Suzuki1, Ikuyo Atsumi1 1: Senju Pharmaceutical Co., Ltd. 2...
https://www.senju.co.jp/rd/society/